Pexa-Vec (pexastimogene devacirepvec) / Transgene, GC Biopharma, SillaJen, Lee's Pharm  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
PHOCUS, NCT02562755 / 2014-001985-86: Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

Hourglass Jan 2019 - Dec 2019 : First data readout from PHOCUS trial of sorafenib in combination with Pexa-Vec vs.sorafenib alone for 1st line advanced liver cancer
Checkmark Data from PHOCUS trial in combination with sorafenib for 1L HCC
Aug 2019 - Aug 2019: Data from PHOCUS trial in combination with sorafenib for 1L HCC
Completed
3
459
Europe, Canada, US, RoW
Pexastimogene Devacirepvec (Pexa Vec), JX-594, Sorafenib, Nexavar
SillaJen, Inc.
Hepatocellular Carcinoma (HCC)
07/20
07/20

Download Options